You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-GTPase HRAS antibody [Y13-259] (ab16881)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-GTPase HRAS antibody [Y13-259]
See all GTPase HRAS products (5) ...

Description

Rat monoclonal [Y13-259] to GTPase HRAS

Specificity

This antibody does not cross-react with rap.

Tested applications

Flow Cyt, ICC, IHC-Fr, IHC-P, WB, IPmore details

Cross reactivity

Reacts with

Mouse, Rat, Human

Immunogen

Recombinant full length protein.

Epitope

Within amino acids 62-76 of v-H-Ras.

Positive control

SW480 or Y1 cells (IP, IB, IF) or normal skin tissue (IHC).

Properties

Form

Liquid

Storage instructions

Store at +4°C. Do not freeze.

Storage buffer

Preservative: 0.1% Sodium Azide
Constituents: 0.2% Gelatin, 0.05M Sodium phosphate

Concentration

Concentration information loading...

Purity

Protein G purified

Clonality

Monoclonal

Clone number

Y13-259

Myeloma

Y3/Ag1.2.3

Isotype

IgG1

  • Flow Cytometry - Anti-GTPase HRAS antibody [Y13-259] (ab16881)Flow Cytometry - Anti-GTPase HRAS antibody [Y13-259] (ab16881) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab16881 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Target

Function

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.

Involvement in disease

Defects in HRAS are the cause of Costello syndrome (COSTS) [MIM:218040]; also known as faciocutaneoskeletal syndrome. Costello syndrome is a rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).

Sequence similarities

Belongs to the small GTPase superfamily. Ras family.

Post-translational
modifications

Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.

Cellular localization

Cell membrane. Golgi apparatus membrane. Shuttles between the plasma membrane and the Golgi apparatus.

Target information above from: UniProt accessionP01112 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • N-terminally processed antibody
  • C BAS/HAS antibody
  • c H ras antibody
  • C HA RAS1 antibody
  • c has/bas p21 protein antibody
  • c ras Ki 2 activated oncogene antibody
  • c-H-ras antibody
  • CTLO antibody
  • GTP and GDP binding peptide B antibody
  • GTPase HRas antibody
  • H Ras 1 antibody
  • H RASIDX antibody
  • H-Ras-1 antibody
  • Ha Ras antibody
  • Ha Ras1 proto oncoprotein antibody
  • Ha-Ras antibody
  • HAMSV antibody
  • HRAS antibody
  • HRAS1 antibody
  • K ras antibody
  • N ras antibody
  • p19 H RasIDX protein antibody
  • p21ras antibody
  • Ras family small GTP binding protein H Ras antibody
  • RASH_HUMAN antibody
  • RASH1 antibody
  • Transformation gene oncogene HAMSV antibody
  • Transforming protein p21 antibody
  • v Ha ras Harvey rat sarcoma viral oncogene homolog antibody
  • VH Ras antibody
  • vHa RAS antibody
see all

Anti-GTPase HRAS antibody [Y13-259] images:

  Flow Cytometry - Anti-GTPase HRAS antibody [Y13-259] (ab16881)

Flow Cytometry - Anti-GTPase HRAS antibody [Y13-259] (ab16881)

Overlay histogram showing HeLa cells stained with ab16881 (red line). The cells were fixed with 80% methanol (5 min) and incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab16881, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-rat IgG (H+L) (ab98386) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was rat IgG1 [RTK2071] (ab18412, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HeLa cells fixed with 4% paraformaldehyde (10 min) used under the same conditions.

Please note that Abcam do not have any data for use of this antibody on non-fixed cells. We welcome any customer feedback.

References for Anti-GTPase HRAS antibody [Y13-259] (ab16881)

This product has been referenced in:

  • Furth MEet al. Expression of ras proto-oncogene proteins in normal human tissues. Oncogene 1:47-58 (1987).Read more (PubMed: 3125507) »
  • Furth MEet al. Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family. J Virol 43:294-304 (1982).Read more (PubMed: 6287003) »

See all 2 publications for this product

Publishing research using ab16881? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"